Asset Details
Do you wish to reserve the book?
A Critical Reappraisal of the 400-μm Corneal Thickness Threshold for Endothelial Safety in Corneal Cross-linking
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Critical Reappraisal of the 400-μm Corneal Thickness Threshold for Endothelial Safety in Corneal Cross-linking
Do you wish to request the book?
A Critical Reappraisal of the 400-μm Corneal Thickness Threshold for Endothelial Safety in Corneal Cross-linking
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Critical Reappraisal of the 400-μm Corneal Thickness Threshold for Endothelial Safety in Corneal Cross-linking
2025
Overview
Purpose:
To critically reassess the scientific foundation of the 400-μm minimum corneal thickness threshold for endothelial safety in standard corneal cross-linking (CXL) with 3 mW/cm2 ultraviolet A (UVA) irradiation.
Methods:
A comprehensive analysis of the foundational studies that established this limit was conducted, with a focus on their methodological assumptions, modeling strategies, and translational weaknesses. Particular attention was given to the use of optical attenuation equations, riboflavin pharmacokinetics, and evolving imaging practices.
Results:
The 400-μm threshold is derived from two seminal studies (one in vitro, one in vivo) that applied fixed assumptions about riboflavin concentration and stromal uniformity. Notably, the models used the Exponential Attenuation law and not the Lambert-Beer law, as opposed to what is frequently cited, to estimate UVA penetration. These estimations relied on simplified optical parameters, such as a uniform attenuation coefficient (μ = 53 cm−1), without accounting for depth-dependent chromophore gradients, scattering, or biological variability. Moreover, the original threshold did not anticipate subsequent changes in riboflavin formulation and concentration, the use of alternative vehicles such as hydroxypropyl methylcellulose, or the emergence of accelerated and customized CXL protocols—factors that materially alter stromal pharmacokinetics and photochemical response.
Conclusions:
The 400-μm guideline, although historically influential, is conceptually fragile. To establish a scientifically robust safety threshold in CXL, future models must incorporate validated attenuation coefficients, experimentally defined riboflavin diffusion dynamics, and patient-specific stromal properties. A more precise, data-driven framework is needed to support individualized decision-making, especially for CXL in thin corneas.
Publisher
SLACK Incorporated,Slack, Inc,SLACK INCORPORATED
Subject
/ Cornea
/ Cross-Linking Reagents - therapeutic use
/ Endothelium, Corneal - drug effects
/ Endothelium, Corneal - pathology
/ Endothelium, Corneal - radiation effects
/ Humans
/ Optics
/ Photosensitizing Agents - pharmacokinetics
/ Photosensitizing Agents - therapeutic use
/ Riboflavin - pharmacokinetics
/ Riboflavin - therapeutic use
/ Safety
